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Abstract
NleG homologues constitute the largest family of type 3 effectors delivered by pathogenic E. coli, with fourteen members in
the enterohaemorrhagic (EHEC) O157:H7 strain alone. Identified recently as part of the non-LEE-encoded (Nle) effector set,
this family remained uncharacterised and shared no sequence homology to other proteins including those of known
function. The C-terminal domain of NleG2-3 (residues 90 to 191) is the most conserved region in NleG proteins and was
solved by NMR. Structural analysis of this structure revealed the presence of a RING finger/U-box motif. Functional assays
demonstrated that NleG2-3 as well as NleG5-1, NleG6-2 and NleG99 family members exhibited a strong autoubiquitination
activity in vitro; a characteristic usually expressed by eukaryotic ubiquitin E3 ligases. When screened for activity against a
panel of 30 human E2 enzymes, the NleG2-3 and NleG5-1 homologues showed an identical profile with only UBE2E2,
UBE2E3 and UBE2D2 enzymes supporting NleG activity. Fluorescence polarization analysis yielded a binding affinity
constant of 5662 mM for the UBE2D2/NleG5-1 interaction, a value comparable with previous studies on E2/E3 affinities. The
UBE2D2 interaction interface on NleG2-3 defined by NMR chemical shift perturbation and mutagenesis was shown to be
generally similar to that characterised for human RING finger ubiquitin ligases. The alanine substitutions of UBE2D2 residues
Arg5 and Lys63, critical for activation of eukaryotic E3 ligases, also significantly decreased both NleG binding and
autoubiquitination activity. These results demonstrate that bacteria-encoded NleG effectors are E3 ubiquitin ligases
analogous to RING finger and U-box enzymes in eukaryotes.
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Introduction
One of the best-studied molecular machineries in bacteria-host
cell interactions is the Type 3 Secretion System (T3SS). The T3SS
is a syringe-like multi-protein complex spanning both the inner
and outer bacterial membranes and the host cell membrane. It
allows various Gram-negative bacteria, including important
human intra- and extracellular pathogens such as Yersinia sp.,
Shigella, Salmonella and pathogenic strains of Escherichia coli as well as
plant pathogens such as Pseudomonas syringae, to inject a set of
specific proteins, known as effectors, directly into the cytoplasm of
the host cell. These effectors then act to alter host responses and
promote the dissemination of bacteria.
There are over a hundred families of confirmed and potential
effectors secreted by the T3SS [1,2,3]. The specific functions of
most of these proteins in the host cell remain unknown. The few
examples of functionally characterised effector proteins highlight
their ability to target a range of key mechanisms in host cells by
mimicking the eukaryote-specific activities that are often not found
in prokaryote biology, such as actin polymerisation [4,5], vesicle
trafficking [6,7] and specific signal transduction pathways unique
to eukaryotes [8,9].
The host ubiquitin proteasome system (UPS) is emerging as one
of the main targets for effector proteins [10,11,12]. The
ubiquitination system involves the specific tagging of proteins by
covalent attachment of single or multiple ubiquitin polypeptide
chains. This modification labels the protein either for degradation
by the 26S proteasome or for other functions such as localisation
to specific cell compartments.
Ubiquitination is a multi-step process that involves at least three
classes of enzymes, designated E1, E2 and E3. The ubiquitin
activating enzyme (E1) first charges ubiquitin in an ATP-
dependent manner to form an E1-ubiquitin thioester intermediate.
This activated ubiquitin is then transferred to the active cysteine of
an ubiquitin conjugating enzyme (E2). The transfer of ubiquitin
from the E2 enzyme to the target protein is mediated by ubiquitin-
protein ligases (E3), which are responsible for the selectivity of the
ubiquitination process. There are possibly hundreds of E3 ligases
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E3 ligases can be divided into two main classes depending of their
functional domains. The first class of E3 ligases contain a HECT
(homologous to E6-associated protein C-terminus) domain; these
enzymes play a direct role in catalysis during ubiquitination [13].
They accept ubiquitin from E2 enzymes via the thioester bound to
their active site cysteine, and then directly transfer the ubiquitin to
the targeted substrates [14,15]. The second class of E3 ligases
contain a RING (really interesting new gene) or a U-box domain
(a modified RING motif which lacks the Zn
2+ ions present in
RING), and act as adaptor-like molecules. This type of E3 ligase
binds to an E2-ubiquitin complex and to the target protein and
activates the transfer of the ubiquitin cargo from the former to the
latter [16,17].
While bacteria lack the UPS, bacterial pathogens secrete many
effectors with UPS-specific functions [10,11,12]. The largest and
most diverse group of effectors known to associate with the host
UPS are those able to mimic the E3 ubiquitin ligase activity. This
category includes the P. syringae pv. tomato (strain DC3000) T3SS
effector AvrPtoB, which provokes the hypersensitive response in
tomato plants expressing the Pto resistance gene [18]. Despite the
fact that AvrPtoB does not share any significant sequence
similarity with eukaryotic E3 ligases, its C-terminal domain is
structurally similar to the U-box domain and functions as an E3
ligase [19]. The role of AvrPtoB has been linked with proteasome
dependent degradation of several plant protein targets, including
tomato kinase Fen [20]. The plant pathogen Ralstonia solanacearum
encodes for seven effectors of the GALA family which have the F-
box motifs that bind the host Skp1 proteins and function as SCF
(Skp1, Cullin, F-Box) E3 ligases [21]. The Salmonella SopA effector
is involved in the regulation of the host inflammatory response and
demonstrated functional and structural features similar to the
HECT E3 ligases [22]. Finally, members of the IpaH effector
family, found in diverse plant and animal pathogens and
symbionts including Pseudomonas sp., Salmonella and Shigella,
comprise a novel class of E3 ligases [23]. The Salmonella
representative of this family, SspH1, binds to and ubiquitinates
the mammalian protein kinase PKN1 [23,24]. The role of IpaH
family proteins in pathogenesis and the identification of their
eukaryotic targets have yet to be elucidated. The conserved C-
terminal domains of these proteins contain an invariant cysteine
that forms a Cys-Ub intermediate similar to the active site Cys of
HECT E3 ligases [25,26]. However, according to the recently
published structures of three members of this family, the Shigella
IpaH1.4 [26] and IpaH3 [25] effectors and Salmonella SspH2 [27]
the C-terminal domain of these effectors does not share any
structural similarity with HECT E3 ligases. The N-terminal
regions of the IpaH family members contain diverse leucine-rich
repeat (LRR) domains apparently responsible for specificity
toward different substrates in the host cell and autoregulation of
E3 activity [23,24,26,27].
The attaching and effacing human pathogen enterohaemor-
rhagic Escherichia coli (EHEC) is the causative agent of diarrheal
disease characterised by bloody diarrhoea and haemolytic uremic
syndrome. In contrast to intracellular pathogens, EHEC use a set
of effectors delivered by the T3SS to subvert actin polymerization
to form the so-called ‘‘pedestal’’ on the host-cell surface which
facilitates adherence and colonisation of the pathogen [4]. The
T3SS apparatus of EHEC is encoded within a specific locus in its
genome named the ‘‘locus of enterocyte effacement’’ or LEE [28].
Effector proteins identified within the LEE were thought to
represent the complete EHEC effector repertoire, since the
transfer of this pathogenicity island alone was sufficient to allow
the non-pathogenic E. coli K12 to induce an attaching and
effacing-like phenotype [29]. However, the recent genome-wide
analysis of EHEC O157:H7 revealed a large number of additional
non-LEE-encoded (Nle) effector proteins, totalling over 20 protein
families [30]. The largest family among these newly identified
effectors was called NleG. The Sakai strain of O157:H7 contains
14 different representatives of this family and over 20 NleG
homologues can be found in different strains of pathogenic E. coli
and Salmonella. NleG proteins have been demonstrated to be
substrates of the T3SS and to be translocated into human cells
[30,31]. The NleG family shares no sequence homology to
proteins of known function. In the current study, we demonstrate
that the most conserved C-terminal portion in NleG effectors is
structurally similar to the RING finger/U-box motif and that these
effectors function in vitro as E3 ubiquitin ligases.
Results
Identification of the conserved C-terminal domain in
NleG proteins
The Pfam database (http://pfam.sanger.ac.uk) identifies 24
NleG homologues found mainly in pathogenic E. coli and
Salmonella genomes. This group of proteins form a distinct family,
dubbed DUF1076 (PF06416), which does not share any significant
sequence similarity with other proteins. NleG family members
demonstrate significant variation in length (from 111 to 223 amino
acids) and sequence, featuring as low as 28% sequence identity
between certain family members. Nevertheless, a comparative
sequence analysis demonstrated that all NleG proteins contain a
conserved region of ,100 residues localised to the C-terminus
(Figure 1). The N-terminal part of NleG proteins appears to be
significantly less conserved.
Based on this analysis, we postulated that the conserved C-
terminal region of NleG proteins might represent a distinct
independently-folding domain. To test this hypothesis, the
corresponding fragment of NleG2-3 from the E. coli O157:H7
strain, spanning from amino acid 90 to 191 (NleG2-3[90–191];
Figure 1) was expressed in
15N enriched minimal medium and
Author Summary
Many bacterial pathogens utilize a multiprotein ‘‘injection
needle’’ termed the type III secretion system to deliver a
set of proteins called effectors into the host cell. These
effectors then manipulate host signalling pathways to the
advantage of the pathogen, often mimicking eukaryote-
specific activities. We present a study of an uncharac-
terised family of effectors called NleG, secreted primarily
by enterohaemorrhagic E. coli (EHEC) O157:H7, a causative
agent of human gastroenteritis. We solved the solution
structure of a conserved C-terminal region of an NleG
family member by NMR. Structural analysis demonstrated
that the NleG structure is similar to the RING finger/U-box
domain found primarily in eukaryotic ubiquitin ligases. The
activity of these domains in eukaryotes is an essential part
of the ubiquitination signalling system. Due to its central
role in cell metabolism and the host immune response, the
ubiquitination system has emerged as a primary target for
bacterial effectors. Our biochemical analysis demonstrated
that NleG proteins selectively interact with human E2
ubiquitin conjugating enzymes and exhibit in vitro activity
typical of eukaryotic E3 ligases. Our data reveal that NleG
effectors structurally and functionally mimic host U-box/
RING E3 ubiquitin ligases. Future research will focus on
determining targets of NleG ubiquitin ligase activity and
the role in E. coli pathogenesis.
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PLoS Pathogens | www.plospathogens.org 2 June 2010 | Volume 6 | Issue 6 | e1000960Figure 1. Multiple sequence alignment of NleG effectors. The amino acid sequence of NleG2-3 (Sakai ID: ECs2156), NleG (ECs1824), NleG99
(ECs1828), NleG2-2 (Ecs1994), NleG2-49 (ECs2229), NleG5-2 (ECs2154), NleG6-1 (ECs1995), NleG6-2 (ECs2155), NleG6-39 (ECs3488), NleG79 (ECs2226),
NleG8-2 (ECs3486), NleG2-19 (ECs1811), and NleG5-1 (ECs1996) were aligned using ClustalX [59]. The secondary structure of the NleG2-3[90–191]
fragment, as determined by NMR, is shown above the alignment. Secondary elements corresponding to the RING/U-box motif are shaded darkly,
while other secondary elements are shaded lightly. Mutation sites are designated with shaded triangle above the alignment when made in NleG2-3
and under the alignment when NleG5-1 was used as template. The positions of the N-terminal amino acid of NleG C-terminal fragments used in this
study are denoted by an asterisk. Residues which were line-broadened upon addition of UBE2D2 are denoted by dark grey spheres above the
alignment.
doi:10.1371/journal.ppat.1000960.g001
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3[90–191] protein fragment showed very good signal dispersion in
1H/
15N-heteronuclear single quantum correlation (HSQC) NMR
spectra (Figure 2A). The number of resolved amide proton peaks
was sufficient to account for all backbone resonances indicating
that this protein fragment is a distinct, independently folded
domain amenable to NMR structure determination.
Solution structure of the NleG2-3 C-terminal domain
Analysis of the NleG2-3[90–191]
1H/
15N-HSQC spectrum
suggested that 57 residues (56% of the total) of NleG2-3[90–191]
exhibited two sets of amide peaks of approximately equal intensity,
indicative of an equimolar mixture of two conformations
(Figure 2A). Complete assignments were obtained for all
resonances that appeared in the
1H/
15N-HSQC spectrum by
the combined use of the automated assignment program FAWN
(Lemak and Arrowsmith, unpublished) and manual analysis.
The assignment of backbone resonances identified two regions
with the largest chemical shift differences between the two
conformations; these span NleG2-3 residues 128 to 143 and
residues 172 to 190 (Figure 2A and 2B). Each of these regions
contains a conserved cysteine residue, at positions 141 and 177,
respectively. The analysis of
13Cb chemical shifts indicated that
Cys141 and Cys177 appear in solution in equal populations of
reduced and oxidised forms (31.96 ppm and 46.11 ppm for
Cys141; 31.02 ppm and 45.61 ppm for Cys177, respectively),
suggesting that while the data collection was performed under
reduced conditions (in the presence of 10 mM DTT, see Methods
for details) the source of the heterogeneity in
15N-HSQC spectra is
the formation of a disulfide bond involving these residues. The
NleG2-3[90–191] fragment contains six cysteine residues, three of
which (Cys119, Cys141 and Cys177) are absolutely conserved in
all NleG homologues (Figure 1). The analysis of
13Cb shifts
demonstrated that all cysteine residues except for Cys141 and
Cys177 appear only in the reduced form (29.31 ppm for Cys101,
28.21 ppm for Cys106, 29.75 ppm for Cys112, 30.20 ppm for
Cys119). Therefore only Cys141 and Cys17are involved in
formation of a disulfide bond. From
15N spin relaxation
measurements, the correlation time of the NleG2-3[90–191]
fragment was estimated to be 5.9 ns (corresponding to a spherical
protein of 12 kDa). This implies that this protein fragment is
monomeric in solution and that the disulfide bond between
Cys141 and Cys177 is intramolecular rather that intermolecular.
Mutation of either Cys141 or Cys177 to alanine resulted in a
reduction in the number of peaks in the
1H/
15N-HSQC spectrum
to a single set (Figure S1), confirming that the heterogeneity
observed in the spectrum of the wild-type NleG2-3[90–191]
fragment is due to the presence of the two species in the sample,
one with and one without an intramolecular disulfide bond
between these cysteine residues.
In order to gain a structural insight onto both ‘‘reduced’’
(featuring Cys141 and Cys177 in the reduced form) and
‘‘oxidised’’ (featuring Cys141 and Cys177 forming a disulfide
bond) conformations of the NleG2-3[90–191] fragment, no further
effort was made to separate these forms in the protein sample over
the course of solution structure determination. Instead the NMR
data were collected on the protein sample containing a mixture of
these conformations, and both conformations of the NleG2-3[90–
191] domain were solved independently.
The NMR solution structures of the ‘‘oxidised’’ and ‘‘reduced’’
NleG2-3[90–191] were generated using automated noeassign/
CYANA iterative calculations and further refined by including
residual dipolar coupling restraints and restrained molecular
dynamic simulations in explicit solvent with the program CNS.
The overall quality of the fit of the residual dipolar couplings
(RDC) to the NleG2-3[90–191] structures after refinement, as
indicated by quality factors (Q) of 0.113 (65
1DNH), 0.206 (68
1DCaCo) and 0.156 (53
1DNCo) for the ‘‘reduced’’ conformation,
and 0.102 (64
1DNH), 0.179 (54
1DCaCo) and 0.137 (48
1DNCo) for
the ‘‘oxidised’’ conformation, respectively (Figure S2), indicate that
the NMR structures provide a good description of the 3D structure
of the NleG2-3[90–191] domain in solution. CS-Rosetta calcula-
tions provide excellent independent cross-validation for the
accuracy of the solution structures of NleG2-3[90–191]. Backbone
superimposition of the best cluster of CS-Rosetta models with
reduced and oxidised NleG2-3[90–191] from residues 91 to 189
gave an r.m.s deviation of 1.9 A ˚ and 1.1 A ˚, respectively. Thus,
solution structures and Rosetta structures are all in good
agreement with respect to the global folding of the NleG2-3[90–
191] fragment. The structural statistics for both conformations are
summarized in Table 1.
The oxidised and reduced NleG2-3[90–191] conformations had
an identical overall fold and superimpose with an r.m.s. deviation
of 1.4 A ˚. The beta carbon atoms of Cys141 and Cys177 forming a
disulphide bridge in the oxidised form remain in close proximity in
the reduced form (i.e. 3.8 A ˚), suggesting that the interchange
between the two observed conformations requires very little
structural alteration. The major difference between the two
NleG2-3[90–191] conformations involves a movement in the
oxidised structure which brings the C-terminal b-hairpin closer to
the long loop (L1) between strand b1 and helix a2. Consequently,
in the oxidised conformation the side chain of Tyr179 aligns with
that of Phe186 filling the space between these elements, while in
the reduced conformation the Tyr179 side chain is exposed to the
solvent (Figure 2C).
NleG2-3 C-terminal domain contains a RING finger/U-box
motif
The analysis of the NleG2-3[90–191] structure revealed the
presence of a motif similar to RING finger/U-box domains. This
part of the NleG2-3[90–191] structure, spanning residues 101 to
172 includes a three-stranded b-sheet (b2–b3, residues 129–145,
and a strand b4, abbreviated to residues 171–172), an a-helix
(helix a2, residues 146–155) and the loops connecting these
elements, dubbed L2, L3 and L4 (Figures 1 and 3A). The tertiary
structure comparison server DALI [32] confirmed the strong
similarity of this region of the NleG2-3[90–191] structure with
several structures of RING-finger/U-box domains, including that
of Pre-mRNA splicing factor Prp19 (PDB 2BAY, Z-score 5.2),
RING finger 38 protein (PDB 1X4J, Z-score 5.0) and the P.
syringae effector AvrPtoB C-terminal domain (PDB 2FD4, Z-score
4.6). The NleG2-3[90–191] structure in the reduced form
superimposes onto the RING finger 38 with an r.m.s. deviation
of 2.3 A ˚ overall except for the very C-terminus of NleG2-3[90–
191], corresponding to the b-hairpin (b5 and b6 strands), this
extreme C-terminus does not have counterparts in otherwise
homologous RING finger structures (Figure 3B).
As mentioned previously, the RING finger is a zinc-chelating
domain found in E3 ubiquitin ligases. The zinc atoms in RING
domains are bound through a set of conserved cysteine/histidine
residues in loops L2 and L4, and are essential for correct folding
and biological activity of the RING domain [16]. In the case of the
U-box, zinc ions are absent so the equivalent fold is maintained by
non-covalent interactions [17]. Analysis of the NleG2-3[90–191]
structure did not reveal any potential metal binding sites ana-
logous to those found in RING finger motifs. The superimposition
of NleG2-3[90–191] and RING finger structures demon-
strated that the conserved cysteine and histidine residues in the
NleG Type 3 Effectors Are E3 Ubiquitin Ligases
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15N-HSQC spectrum of NleG2-3[90–191] at 25uC and pH 7.0. Selected peaks
corresponding to reduced and oxidised conformations are labeled as r (green) and o (blue), respectively. (B) Chemical shift difference (Dppm) between
NleG2-3[90–191] reduced and oxidised conformations plotted against the residue number. Dppm was calculated using the formula Dppm=[(Dd
2
HN +
(DdN/5)
2]
1/2, where dN and dHN are the chemical shift differences for
1HN and
15N between the two forms, respectively. The positions of Cys141 and
Cys177 forming the disulfide bond are denoted. (C) Ensemble of 20 refined structures of NleG2-3[90–191] in the reduced (left) and oxidised (right)
conformations, with the positions of side chains of residues with different conformations between the two forms highlighted. Positions of secondary
structure elements on the reduced conformation are denoted.
doi:10.1371/journal.ppat.1000960.g002
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binding residues in RING domains (see Figure S3A). Finally the
expression of an NleG2-3[90–191] fragment in minimal medium
lacking Zn
2+ ions did not affect its
1H/
15N-HSQC spectrum and
the titration of Zn
2+ ions into this protein sample did not produce
any significant changes in chemical shifts (Figure S3B) features that
have been observed for metal dependent RING domains [33].
This analysis suggests that the NleG2-3[90–191] fold, like those of
the eukaryotic U-box domains and the AvrPtoB C-terminus, does
not depend on the presence of metal ions.
Apart from the ‘‘core’’ RING-finger/U-box motif described
above, the NleG2-3[90–191] structure contains an N-terminal
a-helix (helix a1) which packs against helix a3 and a C-terminal
b-hairpin (strandsb5 andb6,residues177–188) (Figure 3Aand 3B).
These elements do not have counterparts in the otherwise similar
RING-finger/U-box structures mentioned above. Notably the
intra-molecular disulfide bond formed between residues Cys141
and Cys177 in the oxidised NleG2-3[90–191] conformation
connects the C-terminal b-hairpin to the central b-sheet, and may
contribute to the stability of its RING finger motif. However, in the
reduced conformation, the local positions of the cysteine backbone
and Cb atoms remain very similar to that in the oxidised form (the
Cb’s of both Cys141 and Cys177 in the reduced and oxidised forms
superimpose to 1.6 A ˚). Helix a1 in the NleG2-3[90–191] structure
may also contribute to stabilizing the ‘‘core’’ RING-finger/U-box
motif by reducing the solvent accessibility of its central b-sheet.
To conclude, the solution structure of the NleG2-3[90–191]
fragment revealed the presence of a RING-finger/U-box motif.
This motif corresponds to the most conserved portion of NleG
homologues suggesting that this structural element is common
among the members of this family.
NleG proteins demonstrate autoubiquitination activity in
vitro
The RING-finger/U-box domains in eukaryotic E3 ubiquitin
ligases are primarily involved in recruiting and allosteric activation of
the ubiquitin-charged E2 enzyme [16]. As a consequence of this
function, RING-finger/U-box domains are able to promote auto-
Table 1. Structural statistics for the ensemble calculated for
NleG2-3[90–191] solution structure.
NleG2-3[90–191]
‘‘reduced’’
conformation
NleG2-3[90–191]
‘‘oxidized’’
conformation
Distance restraints
All 2806 2949
Intra-residue (i=j) 471 492
Sequential (|i-j|=1) 661 657
Medium range (2#|i–j|#4) 567 591
Long range (|i–j|.4) 1041 1138
Hydrogen bonds 33623 4 62
Disulfide bond - 3
Dihedral angle restraints
All 164 160
w 82 80
Q 82 80
Residual dipolar coupling
restraints
All 186 166
1DNH 65 64
1DNCo 53 48
1DCaCo 68 54
CYANA target function,
(A ˚2)
0.9160.007 1.8960.019
Number of violations
Distance restraints
(.0.5 A ˚)
00
Dihedral angle
restraints (.5u)
00
r.m.s.d from experimental
restraints
Distance (A ˚) 0.016860.0015 0.017260.0010
Dihedral angle (u) 0.537560.1007 0.407460.1405
r.m.s.d from idealized
covalent geometry
bond (A ˚) 0.013560.0002 0.013660.0001
bond angles (u) 0.923160.0182 0.909960.0124
CNS energy (kcal/mol)
Total 23100685 23011676
Van der Waals 271068 272167
Electrostatic 23697683 23596679
r.m.s.d from mean
structure
a
Backbone atoms 0.4560.07 0.3660.06
All heavy atoms 0.8660.11 0.7560.11
Ramachandran plot (%)
a
Residues in most
favored regions
89.6 87.5
Residues in additional
allowed regions
9.9 11.3
Residues in generously
allowed regions
0.5 0.0
Residues in disallowed
regions
0.1 1.1
NleG2-3[90–191]
‘‘reduced’’
conformation
NleG2-3[90–191]
‘‘oxidized’’
conformation
Global quality scores
b Raw Z-score Raw Z-score
Verify3D 0.43 20.48 0.37 21.44
ProsaII 0.72 0.29 0.83 0.74
Procheck (phi-psi)
a 20.32 20.94 20.36 21.10
Procheck (all)
a 20.23 21.36 20.27 21.60
MolProbity clash 17.31 21.44 21.41 22.15
RPF scores
c
Recall 0.939 0.942
Precision 0.957 0.942
F-measure 0.948 0.942
DP-score 0.831 0.820
NleG2-3[90–191] consists of an ensemble of the 20 lowest energy structures out
of 100 calculated.
aRmsd values for residues 91–189.
bCalculated from NESG PSVS program [56].
cRPF scores were defined and calculated by using RPF program [51].
doi:10.1371/journal.ppat.1000960.t001
Table 1. Cont.
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an assay which is commonly used to show E3 ubiquitin ligase activity,
particularly when the target of the E3 ligase is not known [34]. To
investigate if NleG effectors possess such an activity, the full length
NleG5-1[1–213], and NleG99[1–169] proteins, NleG fragments
lacking the predicted N-terminal secretion motif (NleG5-1[62–213],
NleG6-2[17–209], NleG99[61–169] and NleG2-3[55-191]) and
NleG fragments corresponding to the conserved C-terminal region
(NleG5-1[113–213] and NleG2-3[90–191]) (Figure 1) were all tested
in ubiquitination assays in vitro. As a negative control we also tested an
N-terminal fragment lacking the conserved C-terminal domain
(NleG5-1[1–88]). All ubiquitination reactions contained human E1,
UBE2D2 E2 enzyme, which is one of the most versatile enzymes of
this class, ubiquitin and ATP. Western blot analysis using anti-
ubiquitin antibodies allowed visualization of a characteristic pattern
corresponding to multiple polyubiquitinated protein species in the
case of full-length NleG proteins as well as all C-terminal fragments
(Figure 4A). In contrast no ubiquinated protein species were detected
with the NleG5-1[1–88] fragment. The accumulation of polyubiqui-
tinated species was dependant on the presence of each component of
the reaction including E1 and E2 enzymes (Figure 4B), suggesting a
general mechanism similar to that established for eukaryotic E3
RING finger/U-box ubiquitin ligases. Western blot analysis of
products of the His6-NleG5-1[1–213] which represented the only
polyhistidine tagged protein in the ubiquitination reaction, using anti-
polyhistidine antibodies indicated that ubiquitinated protein species
corresponded in part to mono- and poly- ubiquitinated His6-NleG5-
1[1–213] protein (Figure 4C). On the other hand significant amount
of high molecular weight reaction products detected by anti-ubiquitin
antibodies were not recognised by anti-polyhistidine antibodies. Mass
spectrometry analysis (data not shown) of His6-NleG5-1[1–213]
ubiquitination reaction products identified the presence of Lys48 and
Lys63-linked polyubiquitin chains indicating that the high mole-
cular weight products detected by anti-ubiquitin but not by
anti-polyhistidine antibodies correspond primarily to unanchored
polyubiquitin chains. This finding was also supported by the analysis
of products of His6-NleG5-1[1–213] ubiquitination reaction, where
the ubiquitin K0O0 variant was used instead of wild type ubiquitin
(Figure 4C). The use of K0O0 variant, in which all lysine residues are
mutated, prevented the formation of polyubiquitin chains resulting in
complete absence of high molecular weight protein species detected
by anti-ubiquitin antibodies. The only ubiquitinated products
detected in reaction using K0O0 ubiquitin expectably corresponded
to the mono- and multisite ubiquitinated His6-NleG5-1[1–213]
protein species. The formation of unanchored polyubiquitin chains is
often observed as a by-product of in vitro ubiquitination assays of
eukaryotic E3 ubiquitin ligases in the absence of specific ubiquitina-
tion substrate suggesting that autoubiquitination may not be part of
physiological function of NleG5-1.
There are at least thirty E2 enzymes encoded in the human
genome and each E3 ubiquitin ligase is usually selective for only a
few specific E2 enzymes. To investigate the selectivity of NleG
effectors, we tested 30 purified human E2s (for a full list of tested
human E2 enzymes see Table S1) for their ability to support
autoubiquitination of NleG2-3[55–191] and NleG5-1[1–213],
which share only 32% sequence identity. Results from Western
blotting with anti-ubiquitin antibodies, demonstrated that these
NleG proteins have identical E2 specificity profiles (Figure 5A). In
addition to UBE2D2, UBE2D1, UBE2D3, UBE2D4 (which are
all highly homologous), UBE2E2 and UBE2E3 were also able to
support polyubiquitination of both selected NleG proteins. These
data suggest that members of the NleG effector family may share
similar selectivity for human E2 enzymes.
We investigated if the ability to form an intramolecular disulfide
bond in NleG2-3[90–191] is critical for its autoubiquitination
activity in vitro. NleG2-3[90–191] C141A and C177A mutants
were compared with the wild type NleG2-3[90–191] in an
autoubiquitination reaction also containing human E1 and
Figure 3. Overall ribbon diagram of NleG2-3[90–191]. Secondary elements corresponding to the RING/U-box motif are coloured cyan, while
other elements of the structure are coloured green. (A) Overall structure of reduced NleG2-3[90–191] with the N- and C-terminus and secondary
structure elements labelled. (B) Superimposition of reduced NleG2-3[90–191] (same as (A)) with RING finger 38 protein (PDB 1X4J, red); the N- and C-
termini of both molecules labelled.
doi:10.1371/journal.ppat.1000960.g003
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PLoS Pathogens | www.plospathogens.org 7 June 2010 | Volume 6 | Issue 6 | e1000960Figure 4. In vitro activity of NleG proteins. (A) Immunoblot analysis using anti-ubiquitin antibodies of reactions performed in the presence of
ATP, ubiquitin, E1, UBE2D2 and full length or C-terminal fragments of His6-NleG isoforms. (B) Immunoblot analysis with anti-ubiquitin antibodies (top
panel) and SDS PAGE electrophoresis (bottom panel) of reactions performed with ATP and in the presence or absence of ubiquitin, E1, UBE2D2 E2
and NleG5-1[1–203]. (C) Immunoblot analysis with anti-ubiquitin antibodies (top panel) and anti-His6 antibodies (bottom panel) of reactions
performed with E1, wild type ubiquitin (WT) or ubiquitin derivative (K’’O’’) in the presence or absence of His6-NleG5-1[1–203] and UBE2D2 E2 enzyme.
All reactions were incubated at 30uC for the times indicated.
doi:10.1371/journal.ppat.1000960.g004
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PLoS Pathogens | www.plospathogens.org 8 June 2010 | Volume 6 | Issue 6 | e1000960Figure 5. Interaction of NleG2-3 and NleG5-1 with human E2 enzymes. (A) Western blot analysis of reactions using anti-ubiquitin antibodies
performed in presence of ATP, ubiquitin, E1, the indicated human E2 enzymes and either NleG5-1[1–213] (top panel) or NleG2-3[55–191] (bottom
panel). Reactions were performed at 30uC for 2 hours. The asterisk indicates the E2 enzymes supporting formation of multiple ubiquitinated protein
species. The E2 nomenclature is in accordance with that used by the Human Genome Organization (http://www.genenames.org/genefamily/ube2.
php). (B) Immunoblot analysis using anti-ubiquitin antibodies of reactions performed in the presence of ATP, ubiquitin, E1, UBE2D2 and NleG2-3 (left)
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activity of the two cysteine mutants compared to the wild type
(Figure 5B). We also mutated each of the five cysteine residues
(Cys124, Cys142, Cys147, Cys164 and Cys200) in the context of
the full-length NleG5-1 paralogue, which was more easily purified
compared with full-length NleG2-3; Cys164 and Cys200 corre-
spond to Cys141 and Cys177 in NleG2-3 (Figure 1). All five
NleG5-1[1–213] mutants supported formation of polyubiquiti-
nated protein species at a rate comparable to the wild type
(Figure 5C), suggesting that none of the cysteines plays an
obligatory catalytic role. These results combined with the fact that
most of the eukaryotic cellular compartments, the ‘‘mise en sce `ne’’
for NleG proteins, are reducing environments indicating that the
reduced conformation of NleG2-3 may be prevalent in vivo.
In conclusion, the functional assays demonstrated that at least
four NleG effectors display strong autoubiquitination activity in
vitro characteristic to E3 ubiquitin ligases. This activity was
localised to their conserved C-terminal portion, which according
to the NleG2-3[90–191] structure, features a RING/U-box motif.
Interaction of NleG5-1 and UBE2D2
Human UBE2D2 E2 enzyme can support the in vitro activity of
all four of the NleG paralogues tested, namely NleG2-3, NleG5-1,
NleG6-2 and NleG9. To characterise the molecular details of the
interaction of the NleG family and UBE2D2, the UBE2D2 protein
was labelled with fluorescein-5-maleimide and the change in
fluorescence polarization was monitored upon titration with wild
type NleG5-1[1–213] and the corresponding C200A mutant
(Figure 5C). The Kd values for wild-type NleG5-1[1–213] and the
C200A mutant were 5662 and 8163 mM, respectively, suggesting
that the disulfide bond formation in full length NleG5-1 is not
critical for its interaction with UBE2D2. These results are
consistent with the fact that the reduced and oxidised conforma-
tions of the NleG2-3[90–191] have very similar structures and that
they are both functional in ubiquitination assays.
To map the interactions of UBE2D2 with NleG effectors, we
carried out an NMR chemical shiftperturbation experiment in which
unlabeled UBE2D2 protein was titrated into a sample of
15N-labeled
NleG2-3[90–191]. The analysis of
15N-
1H correlations in the
resulting HSQC spectra demonstrated that upon titration of
UBE2D2, the peaks corresponding to NleG2-3 residues Ile121 to
Glu124, Asn134 to Asp136, Asp145, Phe149, Leu152, Leu157,
His159, Leu161, Glu164 and Ala168 disappeared due to strong line
broadening, indicating that these residues may be affected by
interactions with the UBE2D2 enzyme (Figure 6A and 6B).
As described above the
15N-labeled NleG2-3[90–191] sample
represents an equilibrium of the structurally similar reduced and
oxidised conformations. We examined if these conformations
demonstrate any detectable differences in their interactions with
UBE2D2. Such differences would manifest in dissimilar rate of
broadening between oxidised and reduced
15N-
1H correlations of
NleG2-3[90–191] residues upon titration of UBE2D2 protein. We
measured both the peak height and volume of
15N-
1H correlations
of Phe131, Cys177 and Tyr179 NleG2-3 residues, which are the
three resonances showing minimal overlap with other resonances
in both their reduced and oxidised forms over the course of the
titration (Figure 6A). Within the error of these measurements, line
broadening of their oxidised and reduced resonances upon
titration of UBE2D2 occurs at the same rate (data not shown).
Thus no significant difference in interactions with UBE2D2
enzyme was detected for the reduced or oxidised conformations of
NleG2-3[90–191] domain.
Mapping of residues demonstrating significant chemical shift
perturbation upon titration of UBE2D2 enzyme onto the NleG2-
3[90–191] structure established that all these residues belong to
the ‘‘core’’ RING/U-box portion of NleG2-3[90–191] (Figures 1
and 6B). Several residues that undergo significant chemical shift
perturbations upon binding of UBE2D2cluster on the NleG2-
3[90–191] surface in a shallow groove formed by NleG2-3[90–
191] helix a3 and loops L2 and the N-terminus of L4 (Figures 6B
and 6C, see residues 121–124, Asp145, Leu152 and Leu157). This
NleG2-3[90–191] surface area corresponds to the common E2
binding site of eukaryotic RING/U-box domains, which was
recently visualised in the structure of the CHIP E3 ligase U-box
domain in complex with UBE2D2 [35]. The analogous surface
region in the U-box motif of the P. syringae effector AvrPtoB,
involving residues Phe479, Phe525 and Pro533 was shown to be
part of the UBE2D2 E2 binding surface [19]. Superimposition of
the AvrPtoB and NleG2-3[90–1919] structures (Figure 6D)
showed that Phe479, Phe525 and Pro533 residues correspond to
NleG2-3 conserved residues Ile121, Leu152, which demonstrate a
significant line broadening upon binding of UBE2D2 protein and
Pro160, respectively. These observations indicate that the E2
binding site might be conserved between eukaryotic, AvrPtoB and
NleG U-boxes.
Single alanine mutation of Phe479, Phe525 or Pro533 residue
in AvrPtoB has a dramatic effect on its interactions with UBE2D2
enzyme resulting in abolition of AvrPtoB autoubiquitination
activity [19]. Accordingly we probed the effect of mutations of
the corresponding conserved NleG residues on its in vitro
ubiquitination activity. The NleG2-3 Ile121, Leu152 and Pro160
residues were individually substituted by alanine or lysine to
generate a stronger effect. In addition we tested the effect of lysine
substitution of NleG2-3 Leu123 and Asp145 residues. These two
conserved and surface exposed residues also demonstrated
significant chemical shift perturbation upon binding of UBE2D2
protein and are localized adjacent to the potential E2 binding area
described for eukaryotic and AvrPtoB U-boxes (Figure 6A and B).
All eight NleG2-3[90–191] point-mutation variants were tested for
ubiquitination activity by our standard assay. According to the
Western blotting analysis using anti-ubiquitin antibodies
(Figure 6E), both alanine and lysine substitutions of NleG2-3
Ile121 and Leu152 residues led to significant decrease of
ubiquitination activity resulting in diminishing in the formation
of polyubiquitinated protein species. The effect was stronger in
case of lysine substitutions of these NleG2-3 residues resulting in
complete abrogation of formation of polyubiquitinated protein
species at selected time point. In case of Pro160 mutations the
P160K variant also demonstrated dramatic decrease in activity
while P160A variant’s activity was compatible with the wild type
NleG2-3[90–191]. Taken together these results indicated that the
NleG2-3 surface formed by these conserved residues correspond-
ing to the common E2 binding site in eukaryotic RING/U-box
and AvrPtoB E3 ligases might be directly involved in interactions
or NleG5-1 (right) variants. The NleG2-3 variants include the wild type (WT) fragments NleG2-3[55–191] and NleG2-3[90–191] and C141A and C177A
mutants of NleG2-3[90–191]. The NleG5-1 variants included wild type NleG5-1[1–213] and its C124A, C142A, C147A, C164A and C200A mutants. The
samples were incubated at 30uC for the times indicated at the bottom of the panel. (C) Determination of dissociation constants of UBE2D2 with
NleG5-1[1–213] wild type (WT) or its C200A variant. The change in fluorescence polarisation of fluorescein-labeled UBE2D2 is plotted as a function of
NleG5-1 concentration with error bars indicating one standard deviation.
doi:10.1371/journal.ppat.1000960.g005
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PLoS Pathogens | www.plospathogens.org 10 June 2010 | Volume 6 | Issue 6 | e1000960Figure 6. Detailed analysis of NleG interactions with UBE2D2. (A) Overlay of the
1N-
1H HSQC spectrum of
15N-labeled NleG2-3[90–191]
recorded at 25uC in the absence (red) and in the presence (lilac) of unlabeled UBE2D2 at a 1:1 protein ratio. The resonances of NleG2-3 residues
significantly affected by UBE2D2 are labeled. (B) Ribbon diagram of the structure of reduced NleG2-3[90–191] (green) with residues whose NH
resonances were severely line-broadened in
1N-
1H HSQC spectra upon addition of UBE2D2 coloured purple. (C) Surface representation of (B). (D).
Superimposition of AvrPtoB (PDB 2FD4, contact residues and backbone in bleu) and reduced NleG2-3[90–191] (predicted contact residues, purple
and backbone, green), with both structures shown by ribbon diagrams, with selected secondary structure elements of NleG2-3[90–191] and selected
residues from both structures labelled. (E) Immunoblot analysis using anti-ubiquitin antibodies of reactions performed in the presence of ATP,
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PLoS Pathogens | www.plospathogens.org 11 June 2010 | Volume 6 | Issue 6 | e1000960with UBE2D2 enzyme. The lysine substitutions of NleG2-3
Leu123 and Asp145 did not significantly alter the in vitro
ubiquitination activity compared to the wild type NleG proteins
(Figure 6D). The change in chemical shifts of these residues upon
titration of UBE2D2 protein described above may be indicative of
a general conformational adjustment in the NleG2-3[90–191]
molecule upon binding of E2 enzyme rather than of specific
interactions of these NleG residues with the UBE2D2 protein.
From the UBE2D2 perspective the interface involved in
interaction with eukaryotic E3 ubiquitin ligases usually involves
the N-terminal helix and loops 4 and 7 of this E2 enzyme.
However, UBE2D2 specific contacts vary between different RING
E3 ligases [36]. The individual mutations of Arg5, Phe62 and
Lys63 in UBE2D2 residues making contact with the individual
eukaryotic RING E3 ligase, had a dramatic effect on UBE2D2-E3
interactions, resulting in a decrease or complete loss of
corresponding E3 ligase activity [35,37]. To test if these mutations
also affect NleG-UBE2D2 interactions, we examined the effect of
Ala substitutions of Arg5, Phe62 and Lys63 in the UBE2D2
enzyme on the autoubiquitination activity of NleG2-3[90–191]
and NleG5-1[1–213] proteins. Mutation of residues Arg5 and
Lys63 to alanine significantly decreased the autoubiquitination
activity of both NleG2-3[90–191] and NleG5-1[1–213] proteins
(Figure 7B). The effect was more severe in the case of the R5A
mutation, which almost completely abrogated the formation of
polyubiquitinated species by both NleG proteins. The F62A
substitution on the other hand had no noticeable effect on the
activity of NleG2-3[90–191] and NleG5-1[1–213] proteins. In
fact, this UBE2D2 mutant appeared to have higher activity than
wild type UBE2D2 (Figure 7B).
To quantify the NleG5-1[1–213] interactions with UBE2D2
variants, we labelled the three UBE2D2 mutant proteins described
above with fluorescein-5-maleimide and monitored the change in
fluorescence polarization upon titration of NleG5-1[1–213]
(Figure 7C). Kd values for NleG5-1[1–213] interactions with
UBE2D2 R5A, F62A and K63A mutants were 326635, 3662
and 21369 mM, respectively. Compared to the Kd for NleG5-
1[1–213] interaction with wild type UBE2D2, presented above
(5662 mM) the affinity of R5A and K63A mutants were
approximately 5 and 3 times lower, respectively, while the affinity
of the F62A mutant was slightly higher. These affinity values
correlate well with the autoubiquitination assay results. Taken
together, these data suggest that the mutation of UBE2D2 Phe62
to Ala does not significantly affect the UBE2D2-NleG5-1
interactions. On the other hand, the R5A and K63A mutations
in UBE2D2 disrupted the interaction with NleG2-3[90–191] and
NleG5-1[1–213] proteins resulting in a concomitant decrease in
autoubiquitination activity in vitro.
Discussion
We have elucidated the structure and function for the first
member of a large family of type 3 effectors collectively called
NleG. The NleG family accounts for over 20 confirmed and
potential effectors found primarily in pathogenic E. coli with
fourteen members in the O157:H7 strain alone.
Our analysis demonstrated that all NleG effectors feature a
conserved ,100-residue region at the C-terminus which can be
isolated as a soluble domain. The solution structure of this region
from an NleG family member, NleG2-3 (NleG2-3[90–191]),
revealed the presence of a motif structurally similar to the RING-
finger and U-box domains characteristic of E3 ubiquitin ligases.
Subsequent biochemical assays demonstrated that the full length
and C-terminal portion of the NleG2-3 effectors are able to carry
out autoubiquitination in the presence of human E1 and UBE2D2
E2 enzymes in vitro. Two other NleG effectors, namely NleG5-1
and NleG9, and their corresponding C-terminal domains also
demonstrated strong autoubiquitination activity. Thus, the NleG
family representatives share a common function reminiscent of
eukaryotic RING-like E3 ubiquitin ligases.
NMR chemical shift perturbation experiments confirmed that
the RING finger motif in NleG2-3[90–191] plays the primary
role in interactions with the human E2 (UBE2D2) enzyme.
Moreover several conserved NleG2-3[90–191] residues demon-
strating significant chemical shift upon binding of UBE2D2 form
a surface patch corresponding to a common E2 binding site of
eukaryotic RING-like E3 ligases and that of the U-box domain of
P. syringae effector AvrPtoB. Mutations in three conserved NleG
residues that are part of this surface area result in dramatic
decrease of NleG2-3[90–191] and NleG5-1[1–213] ubiquitina-
tion activity. On the E2 side of the E2/NleG interface, the R5A
and K63A mutations of UBE2D2 had a deleterious effect on its
ability to support the autoubiquitination activity of several
RING/U-box proteins; analogous mutations had a similar effect
on the activity of both NleG2-3 and NleG5-1. Overall the
UBE2D2 interactions with NleG effectors appear to follow the
general architecture established for E2/eukaryotic RING finger
complexes.
Similar to other E3 ubiquitin ligases, the NleG2-3 effector
demonstrated selectivity in recognition of E2 enzymes. Apart from
UBE2D2 and its close homologues, only UBE2E2 and UBE2E3
were able to support the autoubiquitination activity of this protein
out of 30 human E2 orthologs that were tested. Notably, the
NleG5-1 effector, which shares only 32% sequence identity with
NleG2-3, demonstrated a similar E2 specificity profile, indicating
that preference in E2 enzymes may be conserved even among
distant NleG homologues.
The significant structural similarity between NleG2-3[90–191]
and the C-terminal domain (CTD) of the P. syringae AvrPtoB
effector (PDB code 2FD4) is of particular interest. The CTD of
AvrPtoB spans residues 436 to 553 (C-terminus) and, until this
work, it represented the only structurally characterised bacterial
effector domain featuring a U-box motif. The ‘‘core’’ U-box motifs
in the AvrPtoB CTD and NleG2-3[90–191] superimpose with an
r.m.s. deviation of 1.59 A ˚ over 41 Ca atoms, while sharing only
18% sequence identity. Along with eukaryotic U-box domains,
both AvrPtoB CTD and NleG2-3[90–191] structures lack the
metal binding sites required for structural integrity of canonical
RING domains. Both the NleG2-3[90–191] and AvrPtoB CTD
domains express strong specificity toward the UBE2D2 family of
E2 enzymes and demonstrate similarly located E2 binding sites as
mentioned above. However the alanine substitutions of residues in
AvrPtoB E2 binding sites appear to have a significantly stronger
effect than similar mutations of equivalent residues in NleG2-3
and NleG5-1. These observations suggest that there may be subtle
differences in the interactions of these proteins with the same E2
enzyme. Functional and structural similarities between AvrPtoB
and NleG U-box domains raise a question of a potential
evolutionary relationship between these bacterial effectors.
ubiquitin, E1, UBE2D2 and NleG2-3[90–191] variants. The NleG2-3 variants include the wild type (WT) fragments NleG2-3[55–191] and I121A, I121IK,
L123K, L152A, L152K, P160A, P160K, E164K and D145K mutants.
doi:10.1371/journal.ppat.1000960.g006
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PLoS Pathogens | www.plospathogens.org 12 June 2010 | Volume 6 | Issue 6 | e1000960Figure 7. Characterisation of UBE2D2 surface interacting with NleG2-3 and NleG5-1. (A) Alignment of the E3 ligase domains of reduced
NleG2-3[90–191] (green) with the CHIP U-box/UBE2D2 complex (PDB 2OXQ) (yellow for the CHIP U-box, cyan for the E2 enzyme), as shown using
ribbon diagrams. The transparent surface of reduced NleG2-3[90–191] is also shown. As with Figure 6, residues in NleG2-3[90–191] whose NH
resonances were severely line-broadened in
1N-
1H HSQC spectrum upon addition of UBE2D2 are coloured purple. Selected residues in UBE2D2 are
shown by a stick representation and labelled, and selected secondary structure elements on the NleG2-3[90–191] ribbon are also labelled. (B)
Immunoblot analysis using anti-ubiquitin antibodies of reactions performed in the presence of ATP, ubiquitin, E1, NleG5-1[1–213] (top and middle
panels) or NleG2-3[90–191] (lower panel) and UBE2D2 wild type (WT) or its R5A, F62A and K63A variants. Samples were incubated at 30uC for the
indicated time. (C) Determination of dissociation constants of NleG5-1[1–213] interactions with UBE2D2 wild type (WT) or its R5A, F62A and K63A
variants. The change in fluorescence polarisation of fluorescein-labelled UBE2D2 and its variants is plotted as a function of NleG5-1[1–213]
concentration with error bars indicating standard deviation.
doi:10.1371/journal.ppat.1000960.g007
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from E2 enzymes onto specific cellular targets. The recognition of
specific target protein(s) is an essential part of this process and is
usually performed by structural elements within the E3 ligase
distinct from its RING finger or U-box. In the case of the AvrPtoB
effector the recognition of its target, namely tomato Fen kinase was
localised to the N-terminal domain (amino acids 1 to 387) of this
protein [20]. The sequence analysis of full length NleG proteins
and structural analysis of the NleG2-3[90–191] fragment present-
ed in this work did not reveal any obvious candidates for a
substrate protein binding motif. Further structural characterisation
of full-length NleG family representatives that would include the
variable N-terminal portion lacking in the current structure is
required to gain insights into the potential location of substrate
binding sites for this novel family of E3 ubiquitin ligases. The lack
of a potential substrate binding motif in NleG effectors also opens
an intriguing possibility that NleG effectors function may be
primarily associated with binding to the specific host E2 enzyme
rather than to the transfer of ubiquitin onto the substrate protein.
Human zinc finger protein A20 (also known as TNFAIP3), which
negatively regulates inflammatory signalling pathways, has been
recently described to inhibit several E3 ligase activities by
antagonizing interactions with the UBE2N (Ubc13) and UBE2D3
(UbcH5c) E2 enzymes [38]. A similar mechanism for the NleG
effectors has yet to be demonstrated experimentally.
Structural and biochemical characterisation of NleG type 3
effectors as E3 ubiquitin ligases opens a new chapter in
identification of their specific role in the host cell. The few
effectors previously characterised with this activity are primarily
involved in suppression of the host immune response by targeting
immune-related host proteins to proteasome degradation. In
Shigella, two diverse members of the IpaH effectors possessing E3
ubiquitin ligase activity were found to target different host proteins
for ubiquitination [23]. The host targets of NleG effectors remain
unknown. Identification of these targets represents the next
challenge in unveiling the function of this important family of
bacterial pathogenic factors.
Materials and Methods
DNA manipulation
His6-tagged constructs of all NleGs used in this study were
amplified from E. coli H157:O7 strain Sakai genomic DNA and
cloned into the T7 expression vector downstream of a DNA
fragment encoding an N-terminal His6 tag followed by a TEV
protease recognition and cleavage site.
Site-directed mutagenesis of NleG2-3, NleG5-1 and UBE2D2
was performed using the QuikChange site-directed mutagenesis kit
(Stratagene) according to the manufacturer’s protocol and verified
by sequencing.
Protein purification
His6-tagged NleGs and His6-tagged E2s were expressed and
purified as previously described [39]. Briefly, the expression
plasmid for each polypeptide was transformed into Escherichia coli
BL21-Gold (DE3) (Stratagene), which harbours an extra plasmid
(pMgk) encoding three rare tRNAs (AGG and AGA for arginine,
and ATA for isoleucine). These E. coli cells were then cultured in 1
litre of Studier medium [40] supplemented with appropriate
antibiotic (ampicillin (100 mg/ml), kanamycin (50 mg/ml) or
chloramphenicol (25 mg/ml)), and incubated at 37uC for 4 hours,
when the culture was allowed to grow overnight at 20uC. Cells
were harvested by centrifugation, disrupted by sonication, and the
insoluble material was removed by centrifugation. His6-tagged
proteins were purified using nickel-nitrilotriacetic acid (Ni-NTA)
affinity chromatography, dialyzed and stored in a buffer
containing 10 mM HEPES, pH 7.5, 300 mM NaCl and
0.5 mM tris-(2-carboxyethyl) phophine (TCEP).
For NMR studies the His6-tagged NleG2-3[90–191] protein
fragment was expressed in E. coli strain BL21-CodonPlus(DE3)-
RIL (Stratagene). Cells were grown in 0.5 L of 2 X M9 minimal
medium containing
15NH4Cl and
13C-glucose as the sole nitrogen
and carbon source and supplemented with ZnSO4, thiamine, and
biotin. The cells were grown at 37uCt oa nO D 600 of 1.0 and
protein expression was induced with 1 mM isopropyl b-D-
thiogalactoside. The temperature was reduced to 15uC, and the
cells were allowed to grow overnight before harvesting. Frozen cell
pellets were thawed in 500 mM NaCl, 20 mM Tris, 5 mM
imidazole (pH 8.0) and lysed by sonication. The proteins were
extracted from the lysates by batch nickel affinity chromatography
(Qiagen). The nickel affinity beads were washed three times with
five column volumes of 500 mM NaCl, 20 mM Tris (pH 8.0),
30 mM imidazole, and the protein was eluted with five column
volumes of 500 mM imidazole in this same buffer. The hexa-
histidine tag was cleaved with TEV protease and the mixture
passed through a nickel affinity column. The purified protein was
concentrated, and buffer was exchanged by ultrafiltration and
dilution/reconcentration into the NMR buffer containing 10 mM
Tris (pH 7.0), 300 mM NaCl, 10 mM DTT, 1 mM benzamidine,
0.01% NaN3, 1 x inhibitor cocktail (Roche Applied Science), 95%
H2O/5% D2O.
NMR spectroscopy
The NMR experiments were carried out at 25uC on either
Bruker Avance 600 or 800 MHz spectrometers equipped with
cryogenic probes. All 3D spectra employed a non-uniform
sampling scheme in the indirect dimensions and were reconstruct-
ed by multi-dimensional decomposition software MDD [41,42],
interfaced with NMRPipe [43]. The backbone assignments were
obtained using HNCO, CBCA(CO)NH, HBHA(CO)NH, HNCA,
and
15N-edited NOESY-HSQC spectra. Assignments were made
initially with the automated program FAWN (Lemak and
Arrowsmith, manuscript in preparation) and followed by manual
analysis with SPARKY (http://cgl.ucsf.edu/home/sparky). Ali-
phatic side chain assignments relied on (H)CCH-TOCSY and
H(C)CH-TOCOSY spectra [44,45]. Aromatic ring resonances
were assigned using 3D
13C-edited NOESY spectra. The
tautomeric states of the histidines were determined by 2D long-
range
15N-
1H HSQC spectrum. Stereospecific valine and leucine
methyl assignments were obtained as described [46] on the basis of
the
13C-
13C one-bond couplings in a high resolution 2D
1H-
13C
HSQC spectrum of 7%-
13C, 100%-
15N NleG2-3[90–191].
Residual dipolar couplings
Three sets of residual dipolar couplings, namely
1DNH,
1DCaCo and
1DNCo, were measured on Bruker Avance 600 MHz spectrometer
from interleaved HNCO-based in-phase/anti-phase (IP/AP) exper-
iments on uniformly
13C,
15N-labelled NleG2-3[90–191] dispersed in
buffer with and without alignment induced from 10 mg/mL Pf1
phages (D2O-splitting=10 Hz) (ASLA, Riga, Latvia). The CaCo-
coupled experiment was additionally acquired with BESTtechnology
[47]. The NH-, CaCo- and NCo-coupled spectrawere acquired with
320632, 406280 and 406280 real + imaginary points, respectively,
in the N and C indirect dimensions and all used the NUS scheme
(30% reduction), followed by MDD reconstruction. The
1J (isotropic
sample) and (
1J+
1D) (anisotropic sample) couplings were measured
from the separation between the two peaks corresponding to the a
and b coherences and isolated in individual sub-spectra after linear
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Peak positions and separation were evaluated in Sparky and
validation was performed with Pales [48].
Structure calculation
Distance restraints for structure calculations were derived from
cross-peaks in
15N-edited NOESY-HSQC (tm=100 ms) and
13C-
edited aliphatic and aromatic NOESY-HSQC in H2O
(tm=100 ms), respectively. NOE peaks were picked and integrat-
ed with the program SPARKY. Automated NOE assignment and
structure calculations were performed using the noeassign module
implemented in the program CYANA, version 2.1 [49]. A total of
164 phi and psi torsion angle restraints for reduced NleG2-3[90–
191] and 160 phi and psi torsion angle restraints for ‘‘oxidised’’
NleG2-3[90–191] were derived from the program TALOS [50].
Hydrogen bond restraints were applied only for residues that were
clearly in the secondary structure regions as judged by NOE
patterns and chemical shifts and supported by TALOS. In
addition, disulfide bond restraints between Cys141 and Cys177
were imposed in the calculation of the ‘‘oxidised’’ conformation of
NleG2-3[90–191]. A total of 94.2% of NOESY peaks were
assigned for both the ‘‘reduced’’ and ‘‘oxidised’’ NleG2-3[90–
191], respectively, in cycle 7. The quality of the noeassign/
CYANA calculation was assessed by NMR structure quality
assessment scores (NMR RPF scores) [51]. The best 20 of 100
CYANA structures from the final cycle were subjected to
restrained molecular dynamics simulation in explicit water by
the program CNS, which was modified to incorporate residual
dipolar couplings [52,53]. The final structures were inspected by
PROCHECK [54] and MolProbity [55] using the NESG
validation software package PSVS [56]. The validation reports
are accessible at http://www.nesg.org. NleG2-3[90–191] is target
ET109A of the Northeast Structural Genomics Consortium and
the Midwest Center for Structural Genomics. Structures were
visualised using the program MOLMOL [57] and Pymol (http://
pymol.sourceforge.net, Delano Scientific).
CS-Rosetta calculation
For reduced NleG2-3[90–191] model prediction, CS-Rosetta
calculations [58] were performed in two steps. First, 10,000 CS-
Rosettamodelsweregenerated.Toevaluate the generated modelswe
used both Rosetta energy and a score that measures compatibility of a
model to unassigned NOESY peak lists. Then the model with the
best-combined score was used as a starting structure in the second
step to generate 2000 Rosetta models. The best cluster consisting of
six models obtained on the second step was selected as a prediction.
For oxidised NleG2-3[90–191] model prediction we generated 2000
model with CS-Rosetta using the reduced NleG2-3[90–191] model
as a starting structure and applying disulfide bond restraints between
residues Cys141 and Cys177.
Titration studies of UBE2D2 and NleG2-3
Titration was performed by adding an aliquot of dilute
unlabelled UBE2D2 in the NMR buffer to a 0.5 mL NMR
sample of
15N-labelled NleG2-3[90–191], the diluted NMR
sample was allowed to stand for at least an hour and then
concentrated back to 0.5 mL. The
15N-HSQC spectra were
recorded after each addition. Only two additions were made until
an ,1:1 ratio of UBE2D2 and NleG2-3[90–191] was formed.
In vitro assays
Ubiquitination reactions were performed in a 20-ml reaction
mixture containing buffer (50 mM Tris?HCl (pH 7.5), 100 mM
NaCl, 10 mM ATP, 10 mM MgCl2, 0.5 mM DTT), 4 mgo f
human ubiquitin (wild type and K0O0, Boston Biochem), 0.13 mg
of E1, 2 mg of E2 and 2 mg of His6-tagged NleGs proteins.
Reactions were incubated at 30uC for the indicated period of time
and stopped by the addition of an equal volume of 2X Laemmli
sample buffer (0.125 M Tris-HCl, pH 6.8, 20% glycerol, 4% SDS,
0.004% bromophenol blue, 100 mM DTT). Reaction mixtures
were separated by SDS-PAGE, transferred onto a nitrocellulose
membrane and probed with specific antibodies.
The collection of human E2 expression constructs was received as
a gift from the S. Dhe-Paganon laboratory at the Structural
Genomics Consortium (http://www.sgc.utoronto.ca/sgc-webpages/
sgc-toronto.php). The constructs provided a T7 promoter-driven
expression of the N-terminal poly-histidine fusion for eachhuman E2
enzyme. The constructs were then transformed into E. coli Bl21-Gold
(DE3) (Stratagene), expressed, and purified using Ni-NTA affinity
chromatography as described above.
Fluorescence polarization assay
The UBE2D2 protein and its R5A, F62A and K63A variants were
each incubated with fluorescein-5-maleimide (Molecular Probes) at a
1:25 molar ratio of E2 to fluorescein-5-maleimide at 4uCf o r1 2h .
Free fluorescent dye was removed by gel-filtration chromatography
followed by dialysis. The completeness of labelling was confirmed by
mass spectroscopy. A starting concentration of the labelled E2
variants of 1 nM was selected according to the extent of conjugated
fluorophore.BindingassayswithNleG5-1variantswereperformedin
the buffer containing 25 mM HEPES, pH 7.5, 0.15 M NaCl, and
0.5 mM TCEP. Fluorescence anisotropy was measured at 25uC
using a ‘‘Synergy 2’’ fluorescence polarization instrument (Biotek)
with the excitation wavelength set at 485 nm and emission
wavelength set at 528 nm. Increasing amounts of NleGs were added
to aliquots of labelled E2protein. Data from four measurements were
averaged and fitted to a single-site binding model using nonlinear
regression with GraphPad Prism 4 (version 4.00 for Windows,
GraphPad Software, San Diego California USA, http://www.
graphpad.com).
Accession codes
The structures of NleG2-3[90–191] in both reduced and
oxidised conformations has been deposited at the Protein Data
Bank with accession codes 2KKX and 2KKY, respectively.
Supporting Information
Table S1 Official nomenclature and most common synonym used
for E2 ubiquitin conjugating enzymes. The E2 nomenclature is in
accordance with that used by the Human Genome Organization
(http://www.genenames.org/genefamily/ube2.php).
Found at: doi:10.1371/journal.ppat.1000960.s001 (0.06 MB
DOC)
Figure S1
1H-
15N HSQC spectra of NleG2-3[90-191] and
mutants (A) NleG2-3[90–191] (blue) and NleG2-3[90–191]
C141A (red) (B) NleG2-3[90-191] (blue) and NleG2-3[90–191]
C177A (magenta).
Found at: doi:10.1371/journal.ppat.1000960.s002 (0.99 MB TIF)
Figure S2 Plots of experimental vs. calculated RDCs for NleG2-
3[90-191] after including RDC restraints in refinement. The
experimental
1DNH,
1DCaCo and
1DNCo values, shown on the
ordinate were measured at 25uC using 10 mg/mL Pf1 phages at
pH 7.0. The calculated RDC values, shown on the abscissa, were
determined using the coordinates of lowest energy structure of
reduced or oxidized NleG2-3[90–191].
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Figure S3 Characterisation of zinc binding interactions with
NleG2-3[90–191]. (A) Overlay of reduced NleG2-3[90–191]
(green) with RING finger 38 protein (PDB 1X4J)(red). Residues
of RING finger 38 involved in binding the 2 Zn ions (shown as
grey spheres) are shown in a stick representation and labelled, as
are the corresponding residues in the NleG C-terminal domain. (B)
Overlay of the
1H-
15N HSQC spectra of NleG2-3[90–191] with
(red) and without (blue) adding Zn
+2 to the sample.
Found at: doi:10.1371/journal.ppat.1000960.s004 (2.60 MB TIF)
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